SRT 2183

Research use only, not for human use.

SRT 2183 is a potent, selective SIRT1 activator with EC1.5 of 0.36 uM.

SRT 2183 is a potent, selective SIRT1 activator with EC1.5 of 0.36 uM, displays good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 uM) and is more potent than Resveratrol; improve insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity in obese mice model.

SRT 2183 (1-10 μM; 24-72 hours) inhibits the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner. SRT 2183 (5-10 μM in Reh cells; 10 μM in Ly3 cells; 24 hours) induces expression of DNA-damage response genes associated with accumulation of phospho-H2A.X levels.SRT2183 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. They are for reference only.SRT 2183 :Cell Proliferation Assay Cell Line:Reh cells, Nalm-6 cells (pre-B acute lymphoblastic leukemia (ALL) cell lines) Concentration:1 μM, 5 μM, 10 μM Incubation Time:24 hours, 48 hours, 72 hours Result:Inhibited the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner. The IC50 (median inhibition concentration) values for SRT 2183-mediated inhibition of proliferation at 48?h are approximately 8.7?μM for Reh cells and approximately 3.2?μM for Nalm-6 cells.Western Blot Analysis Cell Line:Reh cells, Ly3 cells Concentration:5μM and 10μM (Reh cells); 10μM (Ly3 cells)Incubation Time:24 hours Result:Induced accumulation of phospho-H2A.X in Reh as well as in Ly3 cells.

——

SRT2183

Chromatin/Epigenetic

Sirtuin

Sirtuin

Cancer

——

1001908-89-9

468.575

C27H24N4O2S

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (533.54 mM)

O=C(NC1=CC=CC=C1C2=CN3C(SC=C3CN4C[C@H](O)CC4)=N2)C5=CC=C6C=CC=CC6=C5

N-[2-[3-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]naphthalene-2-carboxamide

(-20℃)

With Ice Pack

≥ 2 years